TMPRSS2-ERG gene fusion in prostate cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33154689" target="_blank" >RIV/61989592:15110/15:33154689 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.5507/bp.2014.065" target="_blank" >http://dx.doi.org/10.5507/bp.2014.065</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5507/bp.2014.065" target="_blank" >10.5507/bp.2014.065</a>
Alternative languages
Result language
angličtina
Original language name
TMPRSS2-ERG gene fusion in prostate cancer
Original language description
The TMPRSS2-ERG gene fusion is one of the most widely spread chromosomal rearrangements in cancinomas. Since its discovery, a number of studies have examined its diagnostic, prognostic and therapeutic implications for prostate cancer where suitable biomarkers are still lacking. The publication date are inconsistent. The aim of this review was to critically evaluate the current clinical impact of this gene fusion.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedical Papers-Olomouc
ISSN
1213-8118
e-ISSN
—
Volume of the periodical
158
Issue of the periodical within the volume
4
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
9
Pages from-to
502-510
UT code for WoS article
—
EID of the result in the Scopus database
—